EGRX - Eagle Pharmaceuticals, Inc.
| Previous Close | 43.11 |
| Open | 42.87 |
| Bid | 43.24 x 800 |
| Ask | 73.95 x 800 |
| Day's Range | 42.60 - 44.47 |
| 52 Week Range | 42.60 - 85.66 |
| Volume | 183,197 |
| Avg. Volume | 275,346 |
| Market Cap | 655.286M |
| Beta (3Y Monthly) | 1.67 |
| PE Ratio (TTM) | 23.95 |
| EPS (TTM) | 1.84 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 57.00 |
Markit•9 days agoSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- GlobeNewswire•15 days ago
Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•18 days ago
Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS)
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) today announced positive results of a proof-of-concept (POC) study in a Total-Body Radiation Animal Model. The objective of the study was to evaluate the efficacy of intravenous administration of RYANODEX® to prevent or mitigate Acute Radiation Syndrome (ARS) in a total body irradiated C57BL/6 male mouse hematopoietic model.
- Simply Wall St.•19 days ago
Investors Are Undervaluing Eagle Pharmaceuticals Inc (NASDAQ:EGRX) By 28.8%
Does the November share price for Eagle Pharmaceuticals Inc (NASDAQ:EGRX) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by estimating the company’s future cash flows and Read More...
Markit•21 days agoSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- Business Wire•26 days ago
Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pre
- Zacks•29 days ago
Moving Average Crossover Alert: Eagle Pharmaceuticals (EGRX)
Eagle Pharmaceuticals (EGRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Markit•last monthSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- Thomson Reuters StreetEvents•last month
Edited Transcript of EGRX earnings conference call or presentation 1-Nov-18 12:30pm GMT
Q3 2018 Eagle Pharmaceuticals Inc Earnings Call
Markit•last monthSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- Zacks•last month
Eagle Pharmaceuticals (EGRX) Q3 Earnings Match Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 0.00% and 0.86%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Eagle Pharmaceuticals: 3Q Earnings Snapshot
The Woodcliff Lake, New Jersey-based company said it had profit of 91 cents per share. Earnings, adjusted for non-recurring costs, were $1.18 per share. The specialty pharmaceutical company posted revenue ...
- Business Wire•last month
Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results
-- Q3 2018 net income was $0.94 per basic and $0.91 per diluted share and adjusted non-GAAP net income was $1.22 per basic and $1.18 per diluted share --
- Business Wire•2 months ago
Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase as Part of New $150 Million Share Repurchase Authorization
-- Q3 2018 preliminary EPS is expected to be $0.94 per basic and $0.91 per diluted share --
- Business Wire•2 months ago
Eagle Pharmaceuticals Announces Results of Study for Fulvestrant
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) today announced that the Company’s fulvestrant formulation has not met the primary bioequivalence endpoints evaluating Eagle’s formulation compared to FASLODEX® in its open label, randomized, pharmacokinetic (PK) and safety study conducted in 600 healthy female volunteers across multiple U.S. sites. The Company will continue to evaluate the data, but as a result of this outcome, Eagle intends to focus on advancing the development of other products in its pipeline.
- Business Wire•2 months ago
Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2018 Financial Results on November 1, 2018
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2018 third quarter financial results on Thursday, November 1, 2018, before the market opens.
Markit•2 months agoSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in IAC/InterActiveCorp, Eagle Pharmaceuticals, Arrowhead Pharmaceuticals, The Manitowoc, Brookdale Senior Living, and LATAM Airlines Group S.A — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•2 months ago
Is Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Attractive At Its Current PE Ratio?
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to begin learning about how to Read More...
Markit•2 months agoSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- Business Wire•2 months ago
Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) today announced that it has entered into an agreement with the United States Army Medical Research Institute of Chemical Defense (USAMRICD), the nation's leading science and technology laboratory in the area of medical chemical countermeasures research and development, to conduct a study to evaluate the neuroprotective effects of RYANODEX® (dantrolene sodium). The study will be conducted under a Cooperative Research and Development Agreement (CRADA), a written agreement that allows government laboratories to partner with private industries or academia on research and development projects.
- Business Wire•3 months ago
Eagle Pharmaceuticals, Inc. To Present At Cantor Global Healthcare Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
- Business Wire•3 months ago
Eagle Appoints David Pernock to Position of Chief Operating Officer
Eagle Pharmaceuticals, Inc. today announced that the Compensation Committee of the Company’s Board of Directors has approved the appointment of David Pernock to the position of Chief Operating Officer, effective as of September 1, 2018.
Markit•3 months agoSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- Simply Wall St.•3 months ago
Does Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Fall With The Market?
If you own shares in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
